翻訳と辞書 |
CU-2010 and CU-2020 : ウィキペディア英語版 | CU-2010 and CU-2020
CU-2010 and CU-2020 are new synthetic compounds that act as serine protease inhibitors.〔Szabó, Gábor, et al. "The Novel Synthetic Serine Protease Inhibitor CU-2010 Dose-Dependently Reduces Postoperative Blood Loss and Improves Postischemic Recovery After Cardiac Surgery in a Canine Model." The Journal of thoracic and cardiovascular surgery 139.3 (2010): 732-40. Biological Sciences.〕 These were developed to replace the use of aprotinin during and after cardiac surgery, including surgeries with cardiopulmonary bypass which cause blood loss and hemorrhagic complications.〔"Event Brief of the Medicines Company Acquires CU-2010 and Curacyte Discovery GmbH - Final." Fair Disclosure WireAug 06 2008. ABI/INFORM Trade & Industry.〕 CU-2010 and CU-2020 were developed to avoid many issues associated with the use of aprotinin, including the risk of an allergic reaction and infection. Since the isolation of aprotinin is expensive, a drug with a simpler synthesis was desired.〔Mangano, Dennis T., Iulia C. Tudor, and Cynthia Dietzel. "The Risk Associated with Aprotinin in Cardiac Surgery." The New England journal of medicine 354.4 (2006): 353-65. ProQuest Psychology Journals.〕 ==Chemistry==
CU-2010 has a molecular weight of 700 Da and binds to the active site of serine proteases, like a substrate, due to its peptide-like properties.
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「CU-2010 and CU-2020」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|